Non-coding RNAs in lung cancer: emerging regulators of angiogenesis

Liao, Yajie; Wu, Xudong; Wu, Meng-Yu; Fang, Yuan; Li, Jie; Tang, Weiqiang

doi:10.1186/s12967-022-03553-x

Cited by 21 publications

(5 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Angiogenesis denotes the development of new vessels from existing ones, by which tumor cells acquire sufficient material supplement for their growth (133). Targeting angiogenesis is considered a promising strategy in cancer treatment.…”

Section: Ncrna In Lc Angiogenesismentioning

confidence: 99%

See 1 more Smart Citation

Non-coding RNAs in lung cancer: molecular mechanisms and clinical applications

Liu,

Ding,

Wang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Lung cancer (LC) is a heterogeneous disease with high malignant degree, rapid growth, and early metastasis. The clinical outcomes of LC patients are generally poor due to the insufficient elucidation of pathological mechanisms, low efficiency of detection and assessment methods, and lack of individualized therapeutic strategies. Non-coding RNAs (ncRNAs), including microRNA (miRNA), long non-coding RNA (lncRNA), and circular RNA (circRNA), are endogenous regulators that are widely involved in the modulation of almost all aspects of life activities, from organogenesis and aging to immunity and cancer. They commonly play vital roles in various biological processes by regulating gene expression via their interactions with DNA, RNA, or protein. An increasing amount of studies have demonstrated that ncRNAs are closely correlated with the initiation and development of LC. Their dysregulation promotes the progression of LC via distinct mechanisms, such as influencing protein activity, activating oncogenic signaling pathways, or altering specific gene expression. Furthermore, some ncRNAs present certain clinical values as biomarker candidates and therapeutic targets for LC patients. A complete understanding of their mechanisms in LC progression may be highly beneficial to developing ncRNA-based therapeutics for LC patients. This review mainly focuses on the intricate mechanisms of miRNA, lncRNA, and circRNA involved in LC progression and discuss their underlying applications in LC treatment.

show abstract

Section: Ncrna In Lc Angiogenesismentioning

confidence: 99%

“…As the key regulators of LC progression, ncRNAs have displayed huge therapeutic potential (133). Targeting oncogenic ncRNAs represents a highly feasible solution for patients to improve LC interventions.…”

Section: Ncrna In Lc Treatmentmentioning

confidence: 99%

Non-coding RNAs in lung cancer: molecular mechanisms and clinical applications

Liu,

Ding,

Wang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Recently, studies of non-coding RNAs, including microRNAs, have attracted attention. 7 Accumulating evidence indicates an important role of miRNAs in cancer progression. 8 miRNAs regulate gene expression by promoting messenger RNA degradation or repressing messenger RNA translation.…”

Section: Introductionmentioning

confidence: 99%

A tumor endothelial cell-specific microRNA replacement therapy for hepatocellular carcinoma

Iwamoto,

Suzuki,

Masuda

et al. 2024

iScience

View full text Add to dashboard Cite

“…Consequently, no treatment strategies exist to inhibit VCO. New role players in the angiogenic progression of NSCLC have been described, such as sex dependency and specific non-coding RNAs [ 32 , 37 ]. It is clear that the angiogenic landscape in NSCLC is multifaceted, and various efforts in mechanistic investigation and treatment strategy remain necessary.…”

Section: Introductionmentioning

confidence: 99%

Recombinant Endostatin as a Potential Radiosensitizer in the Treatment of Non-Small Cell Lung Cancer

et al. 2023

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is the most prevalent type of lung cancer, which is the leading cause of cancer-related deaths worldwide. Over the past decades, tumour angiogenesis has been intensely studied in the treatment of NSCLC due to its fundamental role in cancer progression. Several anti-angiogenic drugs, such as recombinant endostatin (RE), have been evaluated in several preclinical and clinical trials, with mixed and often disappointing results. However, there is currently an emerging interest in RE due to its ability to create a vascular normalization window, which could further improve treatment efficacy of the standard NSCLC treatment. This review provides an overview of preclinical and clinical studies that combined RE and radiotherapy for NSCLC treatment. Furthermore, it highlights the ongoing challenges that have to be overcome in order to maximize the benefit; as well as the potential advantage of combinations with particle therapy and immunotherapy, which are rapidly gaining momentum in the treatment landscape of NSCLC. Different angiogenic and immunosuppressive effects are observed between particle therapy and conventional X-ray radiotherapy. The combination of RE, particle therapy and immunotherapy presents a promising future therapeutic triad for NSCLC.

show abstract

Non-coding RNAs in lung cancer: emerging regulators of angiogenesis

Cited by 21 publications

References 104 publications

Non-coding RNAs in lung cancer: molecular mechanisms and clinical applications

Non-coding RNAs in lung cancer: molecular mechanisms and clinical applications

A tumor endothelial cell-specific microRNA replacement therapy for hepatocellular carcinoma

Recombinant Endostatin as a Potential Radiosensitizer in the Treatment of Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About